Literature DB >> 8654164

Effect of ursodeoxycholic acid on HCV replication in subtyped chronic hepatitis C.

M Mohler, S Seipp, U Tox, W Stremmel, L Theilmann, T Goeser.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8654164     DOI： 10.1007/bf02088249

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  9 in total

1.  Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid.

Authors:  Y Calmus; P Gane; P Rouger; R Poupon
Journal:  Hepatology       Date:  1990-01       Impact factor: 17.425

2.  Ursodeoxycholic acid-induced changes of plasma and urinary bile acids in patients with primary biliary cirrhosis.

Authors:  A Stiehl; G Rudolph; R Raedsch; B Möller; U Hopf; E Lotterer; J Bircher; U Fölsch; J Klaus; R Endele
Journal:  Hepatology       Date:  1990-09       Impact factor: 17.425

3.  Ursodeoxycholate reduces hepatotoxicity of bile salts in primary human hepatocytes.

Authors:  P R Galle; L Theilmann; R Raedsch; G Otto; A Stiehl
Journal:  Hepatology       Date:  1990-09       Impact factor: 17.425

4.  A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group.

Authors:  R E Poupon; B Balkau; E Eschwège; R Poupon
Journal:  N Engl J Med       Date:  1991-05-30       Impact factor: 91.245

5.  Immunomodulatory effects of ursodeoxycholic acid on immune responses.

Authors:  M Yoshikawa; T Tsujii; K Matsumura; J Yamao; Y Matsumura; R Kubo; H Fukui; S Ishizaka
Journal:  Hepatology       Date:  1992-08       Impact factor: 17.425

6.  Ursodiol in the long-term treatment of chronic hepatitis: a double-blind multicenter clinical trial.

Authors:  S Bellentani; M Podda; C Tiribelli; F Callea; M Marazzi; M Sodde; R Merlini; P M Batezzati; A Crosignani; M Zuin
Journal:  J Hepatol       Date:  1993-11       Impact factor: 25.083

7.  Transient immunoglobulin M antibody response to hepatitis C virus capsid antigen in posttransfusion hepatitis C: putative serological marker for acute viral infection.

Authors:  P J Chen; J T Wang; L H Hwang; Y H Yang; C L Hsieh; J H Kao; J C Sheu; M Y Lai; T H Wang; D S Chen
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-01       Impact factor: 11.205

8.  The effect of ursodeoxycholic acid on serum enzymes and liver histology in patients with chronic active hepatitis. A 12-month double-blind, placebo-controlled trial.

Authors:  A F Attili; A Rusticali; M Varriale; L Carli; A M Repice; F Callea
Journal:  J Hepatol       Date:  1994-03       Impact factor: 25.083

9.  Significance of IgM antibody to hepatitis C virus in patients with chronic hepatitis C.

Authors:  S Brillanti; C Masci; P Ricci; M Miglioli; L Barbara
Journal:  Hepatology       Date:  1992-06       Impact factor: 17.425
  9 in total
  1 in total

1.  Long-term efficacy of interferon-alpha and ursodeoxycholic acid in treatment of chronic type C hepatitis.

Authors:  H Senturk; O Uzunalimoglu; Y Batur; I Simsek; A Mert; G Ozbay; H Cetinkaya; G Ersoz; F Tabak; H Akbaylar; M Akdogan; A Dokmeci; A Sonsuz; S Ozenirler; E Erden; N Tozum
Journal:  Dig Dis Sci       Date:  1997-07       Impact factor: 3.199
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.